drugset / Trial / NCT02188277

Treatment With Xeomin Versus Botox in Children With Spastic Equine and Equinovarus Foot Deformation in Pediatric Cerebral Palsy

NCT02188277

RandomizedParallel-groupOpen-labelTreatment

Summary

1. To assess the clinical and neurophysiological efficacy of Xeomin® vs. Botox® in children with spastic equine and equinovarus foot deformation in pediatric cerebral palsy 2. To assess the safety of Xeomin® use as compared to Botox® in this patient population

Timeline

Start
2014-07
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic 4 iu/kg Intramuscular
Comparator Botulinum toxin type A Protein / enzyme biologic 6 iu/kg Intramuscular
Comparator Botulinum toxin type A Protein / enzyme biologic 8 iu/kg Intramuscular

Indications